

IN THE CLAIMS

1-9 (Canceled).

10. (Previously Presented) A method of treating a disorder or disease characterized by activation along a signal transduction cascade within the mitogen activated protein kinase (MAPK) superfamily, said method comprising:

administering to a subject in need thereof an effective amount of a therapeutic agent, wherein the agent is a guanylhydrazone-substituted compound.

11. (Previously Presented) The method according to Claim 10, wherein the guanylhydrazone-substituted compound is CNI-1493.

12. (Previously Presented) The method according to Claim 11, wherein treatment is characterized by targeting activation of an upstream or downstream component along the p38 MAPK signaling pathway.

13. (Previously Presented) The method according to Claim 11, wherein the disease or disorder is modulated by inhibiting signaling along a pathway within the cascade.

14. (Previously Presented) The method according to Claim 11, further comprising administering an additional therapeutic agent.

15. (Previously Presented) The method according to Claim 14, wherein the additional therapeutic agent is an anti-viral agent.

16. (Previously Presented) The method according to Claim 14, wherein the additional therapeutic agent is a reverse transcriptase inhibitor.

17. (Previously Presented) The method according to Claim 14, wherein the additional therapeutic agent is an HIV protease inhibitor.

18. (Previously Presented) The method according to Claim 14, wherein the additional

therapeutic agent is a preintegration complex inhibitor.

19. (Previously Presented) The method according to Claim 10, wherein the disease or disorder is modulated by inhibiting signaling along a pathway through p38 MAP kinase within the cascade.